CPRX vs SYF · P/E 18, rev $491.7M vs rev $11.19B
Catalyst Pharmaceuticals Inc (CPRX) versus SYF (SYF) — a side-by-side from cached financials, not a winner call.
Catalyst Pharmaceuticals Inc (CPRX) is a biotechnology company listed on NASDAQ.
SYF (SYF) common stock.
Latest reported CPRX revenue for 2024-12-31 was $491.7M. Net income was $163.9M. Revenue was up 23.5% from 2023-12-31 to 2024-12-31. CPRX currently screens at market cap $3.84B and trailing P/E 18.2.
Latest reported SYF revenue for 2026-06-30 was $11.19B. Net income was $1.69B. Revenue was up 99.6% from 2026-03-31 to 2026-06-30. SYF currently screens at market cap $0.
CPRX currently screens at market cap $3.84B and trailing P/E 18.2. SYF currently screens at market cap $0.
Not investment advice. Open the CPRX and SYF stock pages for the full models.
Not investment advice.